Clinical trial of cladribine combined with cytarabine and liposomal doxorubicin in remission induction of high-risk or refractory acute myeloid leukemia

Clinical trial of cladribine combined with cytarabine and liposomal doxorubicin in remission induction of high-risk acute myeloid leukemia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017569

Enrollment

Unknown

Registered

2018-08-04

Start date

2022-02-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Experinmental group:on the basis of individualized therapy combined with liposomal doxorubicin and medium dose of cytarabine (CLAAG)

Control Group:on the basis of individualized therapy combined with medium dose of cytarabine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to2017 ELN guidelines, acute myeloid leukemia which are grouped into high-risk.

Exclusion criteria

Exclusion criteria: cases not meet the inclusion criterion

Design outcomes

Primary

Measure	Time frame
blast percentage;2-year OS and DFS;	—

Countries

China

Contacts

Public ContactYao Han

Medical Center of Hematology, Xinqiao Hospital

546686852@qq.com+86 13996014516

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026